Advertisement Adimab initiates new independent research collaborations - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Adimab initiates new independent research collaborations

Adimab has entered into an antibody discovery collaboration with Gilead Sciences and started a bispecific antibody collaboration.

Adimab also announced the achievement of technical milestones from its ongoing collaborations with Novartis, Merck, Merrimack, and Genentech.

Adimab CEO Tillman Gerngross said, "We are now expanding our platform into other aspects of antibody discovery, including bispecific and multi-specific formats."

Under the collaboration with Gilead, Adimab will use its discovery platform to identify fully human antibodies against up to two targets selected by Gilead.

The antibodies generated from the collaboration are commercialized by Gilead and Adimab is eligible for upfront payments, preclinical milestones, clinical development milestones and royalties on product sales.

Under the bispecific antibody collaboration with undisclosed partner, Adimab will identify bispecific antibodies that bind two targets selected by the partner, using its discovery platform.

Adimab will gain technical milestones, license fees, clinical development milestones and royalties on product sales, where as the partner has the option to commercialize one or more of the bispecific antibodies generated from the collaboration.